التفاصيل البيبلوغرافية
العنوان:
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
المؤلفون:
Baselga, José , Bradbury, Ian , Eidtmann, Holger , Di Cosimo, Serena , de Azambuja, Evandro , Aura, Claudia , Gómez, Henry , Dinh, Phuong , Fauria, Karine , Van Dooren, Veerle , Aktan, Gursel , Goldhirsch, Aron , Chang, Tsai-Wang , Horváth, Zsolt , Coccia-Portugal, Maria , Domont, Julien , Tseng, Ling-Min , Kunz, Georg , Sohn, Joo Hyuk , Semiglazov, Vladimir , Lerzo, Guillermo , Palacova, Marketa , Probachai, Volodymyr , Pusztai, Lajos , Untch, Michael , Gelber, Richard D , Piccart-Gebhart, Martine , Holmberg, Stig B , 1946
المصدر:
Lancet . 379(9816):633-40
مصطلحات موضوعية:
Surgery , Kirurgi , Cancer and Oncology , Cancer och onkologi , Administration , Oral , Adult , Aged , Antibodies , Monoclonal , Humanized , administration & dosage , adverse effects , Antineoplastic Combined Chemotherapy Protocols , therapeutic use , Breast Neoplasms , chemistry , drug therapy , pathology , surgery , Chemotherapy , Adjuvant , Diarrhea , chemically induced , Drug Administration Schedule , Female , Humans , Infusions , Intravenous , Liver , drug effects , metabolism , Middle Aged , Neoadjuvant Therapy , methods , Paclitaxel , Quinazolines , Receptor , erbB-2 , analysis , antagonists & inhibitors , Treatment Outcome , Tumor Markers , Biological
الوصف:
The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and synergistic antitumour activity in models of HER2-overexpressing breast cancer. We argue that the two anti-HER2 agents given together would be better than single-agent therapy.
الوصول الحر:
https://gup.ub.gu.se/publication/163572Test
قاعدة البيانات:
SwePub
